Complement factor B activation in patients with preeclampsia

Journal of Reproductive Immunology

Volumn 109, Issue , 2015, Pages 94-100

  Velickovic, Ivan ^a   Dalloul, Mudar ^a   Wong, Karen A ^a   Bakare, Olufunke ^a   Schweis, Franz ^a   Garala, Maya ^a   Alam, Amit ^a   Medranda, Giorgio ^a   Lekovic, Jovana ^a   Shuaib, Waqas ^a   Tedjasukmana, Andreas ^a   Little, Perry ^a   Hanono, Daniel ^a   Wijetilaka, Ruvini ^a,d   Weedon, Jeremy ^b   Lin, Jun ^a,c   Toledano, Roulhac d'Arby ^a,d   Zhang, Ming ^a,b  

^a Downstate Health Sciences University   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

^c University Hospital of Brooklyn   (United States)

^d LUTHERAN MEDICAL CENTER   (United States)

Author keywords

Complement; Preeclampsia; Pregnancy

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE;

ADOLESCENT; ADULT; AFRICAN AMERICAN; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DELIVERY; ETHNIC DIFFERENCE; ETHNIC GROUP; FEMALE; FETUS; FETUS BLOOD SAMPLING; HUMAN; HYPOTHESIS; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MATERNAL BLOOD; NEWBORN; PREECLAMPSIA; PREGNANT WOMAN; PRIORITY JOURNAL; RACE DIFFERENCE; UMBILICAL CORD BLOOD; VENOUS BLOOD; BLOOD; CLINICAL TRIAL; ETHNOLOGY; FETUS BLOOD; IMMUNOLOGY; METABOLISM; MORTALITY; MULTICENTER STUDY; PREGNANCY;

ADULT; AFRICAN AMERICANS; COMPLEMENT ACTIVATION; COMPLEMENT FACTOR B; FEMALE; FETAL BLOOD; HUMANS; PRE-ECLAMPSIA; PREGNANCY;

EID: 84928771316     PISSN: 01650378     EISSN: 18727603     Source Type: Journal    
DOI: 10.1016/j.jri.2014.12.002     Document Type: Article

References (46)

1. Abramson S.B., Buyon J.P. Activation of the complement pathway: comparison of normal pregnancy, preeclampsia, and systemic lupus erythematosus during pregnancy. Am. J. Reprod. Immunol. 1992, 28:183-187.
2. Ahn H., et al. Immunologic characteristics of preeclampsia, a comprehensive review. Am. J. Reprod. Immunol. 2011, 65:377-394.
3. American College of Obstetricians and Gynecologists Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists' task force on hypertension in pregnancy. Obstet. Gynecol. 2013, 122:1122-1131.
4. Balasch J., et al. Further evidence against preeclampsia as an immune complex disease. Obstet. Gynecol. 1981, 58:435-437.
5. Boij R., et al. Biomarkers of coagulation, inflammation, and angiogenesis are independently associated with preeclampsia. Am. J. Reprod. Immunol. 2012, 68:258-270.
6. Burwick R.M., Feinberg B.B. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta 2013, 34:201-203.
7. Burwick R.M., et al. Urinary excretion of c5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension 2013, 62:1040-1045.
8. Buurma A., et al. Preeclampsia is characterized by placental complement dysregulation. Hypertension 2012, 60:1332-1337.
9. Celik N., Ozan H. Maternal serum mannose-binding lectin in severe preeclampsia. Clin. Exp. Obstet. Gynecol. 2008, 35:179-182.
10. Chaouat G., et al. Early regulators in abortion and implications for a preeclampsia model. J. Reprod. Immunol. 2009, 82:131-140.
11. Csuka D., et al. Functional analysis of the mannose-binding lectin complement pathway in normal pregnancy and preeclampsia. J. Reprod. Immunol. 2010, 87:90-96.
12. Davis E.F., et al. Cardiovascular risk factors in children and young adults born to preeclamptic pregnancies: a systematic review. Pediatrics 2012, 129:e1552-e1561.
13. Denny K.J., et al. Elevated complement factor c5a in maternal and umbilical cord plasma in preeclampsia. J. Reprod. Immunol. 2013, 97:211-216.
14. Denny K.J., et al. Complement in pregnancy: a delicate balance. Am. J. Reprod. Immunol. 2013, 69:3-11.
15. Derzsy Z., et al. Activation of the complement system in normal pregnancy and preeclampsia. Mol. Immunol. 2010, 47:1500-1506.
16. Foidart J.M., et al. Antibodies to laminin in preeclampsia. Kidney Int. 1986, 29:1050-1057.
17. Girardi G., et al. Complement activation in animal and human pregnancies as a model for immunological recognition. Mol. Immunol. 2011, 48:1621-1630.
18. Haeger M., et al. Complement activation and anaphylatoxin (c3a and c5a) formation in preeclampsia and by amniotic fluid. Obstet. Gynecol. 1989, 73:551-556.
19. Hoffman M.C., et al. Maternal and fetal alternative complement pathway activation in early severe preeclampsia. Am. J. Reprod. Immunol. 2014, 71:55-60.
20. Kaare M., et al. Complement factor H variant Y402H is not a risk factor for preeclampsia in the Finnish population. Hypertens Pregnancy 2008, 27:328-336.
21. Lenhart P.M., et al. Adrenomedullin signaling pathway polymorphisms and adverse pregnancy outcomes. Am. J. Perinatol. 2014, 31:327-334.
22. Lillegard K.E., et al. Complement activation is critical for placental ischemia-induced hypertension in the rat. Mol. Immunol. 2013, 56:91-97.
23. Liu C., et al. Proteomic analysis of human serum for finding pathogenic factors and potential biomarkers in preeclampsia. Placenta 2011, 32:168-174.
24. Lynch A.M., Salmon J.E. Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta 2010, 31:561-567.
25. Lynch A.M., et al. Alternative complement pathway activation fragment bb in early pregnancy as a predictor of preeclampsia. Am. J. Obstet. Gynecol. 2008, 198(38):e1-e9.
26. Lynch A.M., et al. The interrelationship of complement-activation fragments and angiogenesis-related factors in early pregnancy and their association with pre-eclampsia. BJOG 2010, 117:456-462.
27. Lynch A.M., et al. Early elevations of the complement activation fragment c3a and adverse pregnancy outcomes. Obstet. Gynecol. 2011, 117:75-83.
28. Mannisto T., et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation 2013, 127:681-690.
29. Nakimuli A., et al. Pregnancy, parturition and preeclampsia in women of African ancestry. Am. J. Obstet. Gynecol. 2014, 210:510-520.e1.
30. Qing X., et al. Targeted inhibition of complement activation prevents features of preeclampsia in mice. Kidney Int. 2011, 79:331-339.
31. Rampersad R., et al. The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro. Placenta 2008, 29:855-861.
32. Roberts J.M., Bell M.J. If we know so much about preeclampsia, why haven't we cured the disease?. J. Reprod. Immunol. 2013, 99:1-9.
33. Robillard P.Y., et al. Fourteen years of debate and workshops on the immunology of preeclampsia. Where are we now after the 2012 workshop?. J. Reprod. Immunol. 2014, 101-102:62-69.
34. Saito S., Nakashima A. A review of the mechanism for poor placentation in early-onset preeclampsia: the role of autophagy in trophoblast invasion and vascular remodeling. J. Reprod. Immunol. 2014, 101-102:80-88.
35. Salmon J.E., et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011, 8:e1001013.
36. Singh J., et al. Role of complement component C1q in the onset of preeclampsia in mice. Hypertension 2011, 8:716-724.
37. Soto E., et al. Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products. J. Matern. Fetal Neonatal Med. 2010, 23:646-657.
38. Stanek J., Al-Ahmadie H.A. Laminar necrosis of placental membranes: a histologic sign of uteroplacental hypoxia. Pediatr. Dev. Pathol. 2005, 8:34-42.
39. Stirrat G.M., et al. Circulating immune complexes in pre-eclampsia. Br. Med. J. 1978, 1:1450-1451.
40. Tanaka M., et al. Racial disparity in hypertensive disorders of pregnancy in New York state: a 10-year longitudinal population-based study. Am. J. Public Health 2007, 97:163-170.
41. Testa L., et al. Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J. Thorac. Cardiovasc. Surg. 2008, 136:884-893.
42. Than N.G., et al. A role for mannose-binding lectin, a component of the innate immune system in pre-eclampsia. Am. J. Reprod. Immunol. 2008, 60:333-345.
43. Wallis A.B., et al. Secular trends in the rates of preeclampsia, eclampsia, and gestational hypertension, United States, 1987-2004. Am. J. Hypertens. 2008, 21:521-526.
44. Wang C.C., et al. Innate immune response by ficolin binding in apoptotic placenta is associated with the clinical syndrome of preeclampsia. Clin. Chem. 2007, 53:42-52.
45. Wang W., et al. Autoantibody-mediated complement c3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension 2012, 60:712-721.
46. Zhang S., et al. Racial disparities in economic and clinical outcomes of pregnancy among medicaid recipients. Matern. Child Health J. 2013, 17:1518-1525.